0001367644-22-000043.txt : 20220302 0001367644-22-000043.hdr.sgml : 20220302 20220302192515 ACCESSION NUMBER: 0001367644-22-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Havey Adam CENTRAL INDEX KEY: 0001514588 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 22705944 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20853 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 wf-form4_164626708631194.xml FORM 4 X0306 4 2022-02-28 0 0001367644 Emergent BioSolutions Inc. EBS 0001514588 Havey Adam 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 0 1 0 0 EVP, Business Operations Common Stock 2022-03-01 4 A 0 32323 0 A 69117 D Common Stock 2022-03-01 4 A 0 17822 0 A 86939 D Common Stock 2022-02-28 4 F 0 739 39.64 D 86200 D Employee Stock Options (Right to Buy) 41.38 2022-03-01 4 A 0 42289 41.38 A 2029-02-28 Common Stock 42289.0 42289 D Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (10,573 shares) or on the day prior to the second anniversary date of the grant (21,750 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. /s/ S. Scott Lieberman, Attorney-in-fact 2022-03-02